CHICAGO: Study design

1
CHICAGO Study design
Double-blind, randomized, active control,
parallel-efficacy study Type 2 diabetes,
asymptomatic for CAD N 462
Pioglitazone 15, 30, or 45 mg
Glimepiride 1, 2, or 4 mg
Primary outcome Change in carotid intima-media
thickness at 18 months
Secondary outcome Carotid artery calcium score
NIH. www.clinicaltrials.gov. Mazzone T. Am J
Cardiol. 200493(suppl)27C-31C.

Titrated to reach glycemic control